Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose-lowering agents. RESEARCH DESIGN AND METHODS: After a 6-week run-in when iGlar was introduced and/or further titrated, and oral antidiabetic drugs other than metformin were stopped, 736 basal insulin-treated patients (mean diabetes duration 12 years, BMI 31 kg/m2) were randomized 1:1 to open-label, once-daily iGlarLixi or iGlar, both titrated to fasting plasma glucose <100 mg/dL (<5.6 mmol/L) up to a maximum dose of 60 units/day. The primary outcome was change in HbA1c levels at 30 weeks. RESULTS: HbA1c decreased from 8.5% (69 mmol/mol) to 8.1% (65 mmol/mol) during the run-in period. After randomization, iGlarLixi showed greater reductions in HbA1c from baseline compared with iGlar (–1.1% vs. –0.6%, P < 0.0001), reaching a mean final HbA1c of 6.9% (52 mmol/mol) compared with 7.5% (58 mmol/mol) for iGlar. HbA1c <7.0% (53 mmol/mol) was achieved in 55% of iGlarLixi patients compared with 30% on iGlar. Mean body weight decreased by 0.7 kg with iGlarLixi and increased by 0.7 kg with iGlar (1.4 kg difference, P < 0.0001). Documented symptomatic hypoglycemia (≤70 mg/dL) was comparable between groups. Mild gastrointestinal adverse effects were very low but more frequent with iGlarLixi. CONCLUSIONS: Compared with iGlar, a substantially higher proportion of iGlarLixi-treated patients achieved glycemic targets with a beneficial effect on body weight, no additional risk of hypoglycemia, and low levels of gastrointestinal adverse effects in inadequately controlled, basal insulin-treated, long-standing type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In studies of people with type 2 diabetes inadequately controlled on basal insulin or GLP-1 RA, switching to a fi xedratio combination of basal insulin and GLP-1 RA demonstrated signi fi cant improvements in blood glucose levels and achievement of glycemic goals with fewer hypoglycemic events than with basal insulin alone (216 -220).”
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“mitigate the weight gain observed with insulin therapy (4,6–9); GLP-1 RAs do, however, present a risk of gastrointestinal adverse events (AEs), leading to frequent discontinuations (10).”
BackgroundSelf-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Basal Insulin Therapy in Type 2 Diabetes
Rosenstock, J., Schwartz, S. L., Clark, C. M., Park, G. D., Donley, D. W., & Edwards, M. B. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.631 · Cited by 478 · cited 1×
“Basal insulin therapy improves fasting plasma glucose (FPG) and nocturnal hypoglycemia (3), whereas GLP-1 RAs, especially the short-acting compounds, have a significant effect on postprandial plasma glucose (PPG) (4–9).”
BackgroundSelf-citationAmerican Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-er09 · Cited by 379
Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288 · cited 1×
“treatment, generally in the 25–30% range (7,9,12).”
Self-citationMeier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Self-citationSeino, Y., Min, K. W., Niemoeller, E., Takami, A., & on behalf of the EFC10887 GETGOAL‐L Asia Study Investigators (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01618.x · Cited by 255
Self-citationRiddle, M. C., Forst, T., Aronson, R., Sauque-Reyna, L., Souhami, E., Silvestre, L., Ping, L., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2462 · Cited by 253
Self-citationLingvay, I., Manghi, F. P., García-Hernández, P., Norwood, P., Lehmann, L., Tarp-Johansen, M. J., Buse, J. B., & for the DUAL V Investigators (2016) · JAMA · doi:10.1001/jama.2016.1252 · Cited by 220 · cited 1×
“combination of insulin degludec and the GLP-1 RA liraglutide (17).”
Background
Research works printed but not linked: 2
- Aroda, 2016, Efficacy and safety of the insulin glargine/lixisenatide fixed-ratio combination vs. insulin glargine in patients with T2DM: the LixiLan-L Trial, Diabetes Care, 65, A62
- Sikirica, 2015, Reasons for discontinuation of GLP-1 receptor antagonists: data from a large cross-sectional survey of physicians and type 2 diabetic patients (Abstract), Diabetes Care, 64, A297
Cited by
Items 201–258 of 258
Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist
Lee, I., & Kang, E. S. (2019) · Journal of Korean Diabetes · doi:10.4093/jkd.2019.20.3.149 · Cited by 2
Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c.
Chung, J. W., Hartzler, M. L., Smith, A. A., Hatton, J., & Kelley, K. W. (2018) · Europe PMC (PubMed Central) · Cited by 5
Transitioning to non-insulin therapy in a patient receiving high dose insulin
Mishriky, B. M., Cummings, D. M., Mendez, C. E., Patil, S. P., & Powell, J. R. (2020) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000403 · Cited by 2
“The concept of adding a GLP-1RA to patients already on insulin has already been investigated (Aroda et al., 2016; Guja et al., 2018; Lingvay et al., 2016; Pozzilli et al., 2017; Rodbard et al., 2018) but not extensively in people on high insulin doses (Lane, Weinrib, & Rappaport, 2011; Vanderheiden et al.”
BackgroundJammah, A. A. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.08.004 · Cited by 2
Fonseca, V. A., Sood, M., & Galindo, R. J. (2021) · Clinical Diabetes · doi:10.2337/cd20-0121 · Cited by 2
Austrian Experience with Lixisenatide Under Real-Life Conditions: A Prospective Observational Study
Brath, H., Abrahamian, H., Karuza, T., Mihaljevic, R., & Pfohl, M. (2019) · Diabetes Therapy · doi:10.1007/s13300-018-0558-2 · Cited by 2
Gautier, T., Silwal, R., & Breton, M. D. (2020) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2020.12.649 · Cited by 3
Tratamiento farmacológico del paciente que vive con diabetes mellitus tipo 2
Rincón, A. R., Betancur, S. S., Ramos, A. F. G., González-Arango, J., & Vargas, L. V. E. (2022) · CES Medicina · doi:10.21615/cesmedicina.6672 · Cited by 1
Ken-Opurum, J., Srinivas, S. S. S., Jain, D., Shah, T., Samnaliev, M., DEX, T. A., Charland, S. L., Revel, A., & Preblick, R. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01477-3 · Cited by 1
“The LixiLan-L trial demonstrated that iGlarLixi was associated with a significant decrease in HbA1c compared to iGlar ( - 0.5%; 95% confidence interval [ - 0.6, - 0.4]; p \ 0.001) without an increased risk of hypoglycemia in patients with T2DM [12].”
MethodInfluentialYang, W., Guo, X., Lauand, F., Li, L., Fang, H., Du, Q., & Kang, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15414 · Cited by 1
“18 Previous randomized trials showed the efficacy and safety of iGlarLixi in US and European PwT2D with uncontrolled T2D previously treated with OADs (LixiLan-O), 19 BI plus OADs (LixiLan-L and SoliMix) 20,21 or daily or weekly GLP-1 RA plus OADs (LixiLan-G), 22 as well as in Japanese people with uncontrolled T2D prev…”
Fixed ratio combinations GLP-1RA and basal insulin: literature review
Куркин, Д. В., Bakulin, D. A., Morkovin, E. I., Strygin, A. V., Gorbunova, Y. V., Волотова, Е. В., Robertus, A. I., Макаренко, И. Е., Saparova, V. B., Васильевич, Д. Р., et al. (2024) · Problems of Endocrinology · doi:10.14341/probl13312 · Cited by 5
“Таким образом, иГларЛикси оказался эффективнее дотитрации инсулина гларгин с преимуществами по вли-янию на массу тела [17].”
Gu, W., Wu, X., Zhang, M., Wang, X., Du, Q., Kang, L., Lauand, F., Alvarez, A., & Mu, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70181 · Cited by 1
Yu, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70192 · Cited by 1
Wang, X., Qin, J., Liu, Y., & Wang, X. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70293 · Cited by 1
Gysling, E. (2017) · pharma-kritik · doi:10.37667/pk.2017.1021 · Cited by 1
Song, L., Yuan, X., Huang, S., Zhang, Y., Lauand, F., Wang, Z., Zhang, J., Du, Q., Kang, L., Yang, W., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16260 · Cited by 1
Home, P. D., Lauand, F., Djaballah, K., Li, X., Hafidh, K., Mehta, R., Faraoun, K., Anaforoğlu, İ., Serafini, P. R., & Pourrahmat, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16360 · Cited by 1
“10,11 In addition, PPG was measured using a standardized meal test in Aroda et al. 7 and was not assessed in Rosenstock et al. 9 In the IDegAsp trials, PPG was self-measured.”
InfluentialBlonde, L., & Fonseca, V. A. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0293 · Cited by 2
Rosenstock, J., Blonde, L., Aroda, V. R., Frías, J. P., Souhami, E., Ji, C. F., Niemoeller, E., & Prato, S. D. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14345 · Cited by 1
“iGlarLixi, a once-daily injectable FRC of basal insulin glargine 100 units/mL (iGlar) and the short-acting GLP-1 RA lixisenatide (Lixi), has been shown to be well tolerated and efficacious in people with T2D inadequately controlled by either OADs (LixiLan-O study) or basal insulin (LixiLan-L study).(4,5) LixiLan-G was…”
BackgroundSelf-citationGautier, T., Silwal, R., Saremi, A., Boss, A., & Breton, M. D. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211015671 · Cited by 1
Eggert, S., Zimmermann, E., & Begtrup, K. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1444882 · Cited by 1
“OADs [5,6], and some on maximum tolerated dose of a GLP-1 RA [7].”
BackgroundYoshikawa, F., Uchino, H., Nagashima, T., Usui, S., Miyagi, M., Ando, Y., Kumashiro, N., & Hirose, T. (2020) · Preprints.org · doi:10.20944/preprints202002.0124.v1
and, C. R., & Petrie, J. R. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch6 · Cited by 1
The role of emerging insulin and regimens in overcoming insulin treatment resistance
Barag, S., Meshefedjian, T., & Diep, K. (2017) · Integrative Obesity and Diabetes · doi:10.15761/iod.1000194
“Symptomatic hypoglycemia with a blood sugar of <70mg/dL was comparable between both groups [13].”
BackgroundA practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes
Goldenberg, R., Assimakopoulos, P., Gilbert, J. D., Gottesman, I. S., & Yale, J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13337
“4% of the iGlarLixi participants.(76) A meta-analysis of 10 trials that compared GLP-1RA plus basal”
BackgroundBeyond oral antidiabetics: Insulin therapy options and combinations
Lofton, J. C. (2017) · Pharmacy Today · doi:10.1016/j.ptdy.2017.05.030 · Cited by 1
Wm, V.-R. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_62
Efficacy and Safety of Iglarlixi in Hispanics and Non-Hispanic Whites with Type 2 Diabetes
Mora, P. F., Chao, J., Saremi, A., DEX, T. A., Roberts, M., & Umpierrez, G. E. (2019) · Endocrine Practice · doi:10.4158/ep-2018-0615
IGlarLixi – bázisinzulin és GLP-1-receptoragonista új fix kombinációja
Winkler, G. (2018) · Diabetologia Hungarica · doi:10.24121/dh.2018.2
“A kombináció klinikai eredményességét két nagy vizsgálatban, korábban csak orális antidiabetikus kezelésben részesülőkön (LixiLan-O), illetve bázisinzulint is kapókon (LixiLan-L) tanulmányozták.(8,9) A klinikai vizsgálatokat azután számos post hoc analízisnek is alávetették.”
InfluentialАнциферов, М. Б., Koteshkova, O. M. K., & Demidov, N. A. D. (2020) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2020-16-12-68-73
Modern Drugs in the Treatment of Type 2 Diabetes Mellitus
Маража, І. О., Nazarova, D. I., & Kramar, S. B. (2021) · Ukraïnsʹkij žurnal medicini bìologìï ta sportu · doi:10.26693/jmbs06.04.015
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_20 · Cited by 1
Antsiferov, M. B., Koteshkova, O. M. K., Духарева, О. В., Александрович, Д. Н., & Ermakova, E. A. (2020) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2020-16-26-38-42
Yale, J., de Climens, A. R., Aggarwal, N., DEX, T. A., Gerstein, H. C., Harris, S. B., HRAMIAK, I. M., Stewart, J. A., & Leiter, L. A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01353-6
“This is likely to improve adherence to and persistence with therapy, which may translate to a positive impact on real-world effectiveness that is consistent with the outcomes of the LixiLan-O and LixiLan-L studies [8, 11].”
ResultValencia, W. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_66 · Cited by 3
Chauhan, A., Samnaliev, M., Ken-Opurum, J., Srinivas, S. S. S., Mehta, A. M., DEX, T. A., Charland, S. L., Revel, A., & Preblick, R. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01419-z
“1500 mg when patients were intolerant [12], while in the Lixilan-L trial, iGlarLixi achieved a greater reduction in A1C compared to iGlar [13].”
ResultGarnica-Cuéllar, J. C., Morales-Villegas, E., López-Forero, C. A., Monroy-Cruz, B., Pariti, B., Deshwal, S., Sekharan, M., Osorio-Hernández, M., & García-Appendini, I. C. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-023-00421-2
“sources for the ITC: IDegLira trials—DUAL II [23] and DUAL V [18]; IGlarLixi trials—LixiLan-L [24].”
MethodAbusalem, A. A., & Albalawi, A. R. (2023) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2023.95256162
Butt, S., Akhtar, T., Arif, I., Sagheer, Z., Masood, S., & Farooq, A. (2023) · doi:10.53555/jptcp.v30i18.3538
Delphi, B. (2023) · The Journal of AMD · doi:10.36171/jamd23.26.4.3
Variabilidad de la glucosa como indicador de mortalidad en pacientes con shock séptico
Nickolas Ponce, G., Delgado, D., & Luis Gonzalez, Z. (2024) · Gaceta Médica de la Junta de Beneficencia de Guayaquil · doi:10.61708/sygj5d47
Hussain, I., MacLeod, J., Dunn, F., Bickel, P. E., Abreu, M., McNulty, N., Lingvay, I., Kermani, A., & Abreu, M. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch03
Мисникова, И. В., Kovaleva, Y. A., & Andropova, M. A. (2024) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2024-52-044
Yanovskaya, E. A., & Яновская, М. Е. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-2-08
Hassanein, M. M., Alessa, T., Hafidh, K., Alzubaidi, L. M. Y., Jallo, M. K. I., Slail, F. Y. A., Elbadawi, H., & Malik, R. A. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01824-6
Huang, C., Yang, S. N., Cheng, C.-P., Lin, C., Lee, Y. S., & Chen, H.-S. (2026) · Diabetic Medicine · doi:10.1111/dme.70275
“10,11 Traditionally, insulin therapy in T2DM follows a step-wise intensification approach, beginning with a single daily basal insulin injection and intensifying to basal-plus or basal–bolus regimens as needed.”
Gautham, K., Holla, S. K., & Dasara, B. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-026-01648-5
Saab, C., Mansour, A. A., Rahmah, A. M., Al-Attar, D. M. R. A., Alrubaye, H. F., Alidrisi, H. A., Nwayyir, H. A., Khudhair, M. S., Ahmed, M. J., AL-Ibrahimi, S. M., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01861-9
Assaad-Khalil, S. H., Abdelaaty, T., Rizk, M. N., Megallaa, M. H. Z., Elsayed, M., Wafa, A. M., Ismail, A., Sharafeldeen, B., & Amin, N. G. (2026) · Diabetology · doi:10.3390/diabetology7050090
“In the study by Aroda et al., iGlarLixi was administered 1 h before breakfast [50].”
InfluentialZhou, L., Wu, P., Xu, Y., & Xie, B. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02697-2 · Cited by 2
Urhan, E. (2026) · Anadolu Kliniği Tıp Bilimleri Dergisi · doi:10.21673/anadoluklin.1840385
Li, X., Wang, J., Liu, T., Alvarez, A., Lauand, F., Melas‐Melt, L., Kang, L., Du, Q., & Liu, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70902
Arteaga-Díaz, J. M., Torres-Grajales, J. L., Sauque‐Reyna, L., Salamanca‐Carrillo, C., & Anguiano, L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71018
Ni, J., Lu, J., Gao, F., Li, M., Zhang, M., Du, Q., Kang, L., Peng, D., & Zhou, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71036
Zhang, S., Gu, Y., Cheng, Y., Hu, Y., Li, B., Alvarez, A., Lauand, F., Melas‐Melt, L., Zhang, M., Jiang, Y., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71057 · Cited by 1
(2026) · ADA Clinical Compendia · doi:10.2337/db20261-33
Giorgino, F., Haluzík, M., Alvarez, A., Lauand, F., Assaad-Khalil, S. H., Thacker, H. P., Klupa, T., Deyneli, O., & Rosenstock, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71436
Self-citation
Metadata
- Authors
- Aroda, V. R., Rosenstock, J., Wysham, C., Unger, J., Bellido, D., González-Gálvez, G., Takami, A., Guo, H., Niemoeller, E., Souhami, E., Bergenstal, R. M., & on behalf of the LixiLan-L Trial Investigators
- Affiliations
- MedStar Health Research Institute (US)
- Dallas Diabetes Research Center (US)
- Rockwood Clinic (US)
- Catalina Research Institute (US)
- Universidade da Coruña (ES)
- Universidad de Guadalajara (MX)
- Sanofi (Japan) (JP)
- Biostatistics, BMD Consulting Inc., Somerset, NJ
- Sanofi (Germany) (DE)
- Sanofi (France) (FR)
- Park Nicollet Health Services (US)
- Corresponding author
- Aroda, Vanita R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-09-20
- Volume
- 39
- Issue
- 11
- Pages
- 1972-1980
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2521422828
- Cited by
- 260
- References
- 16
- Citations by year
- 2026: 15 · 2025: 19 · 2024: 24 · 2023: 23 · 2022: 24 · 2021: 27 · 2020: 28 · 2019: 26 · 2018: 46 · 2017: 28
- FWCI
- 33.47
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-06-01)
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin glargine, lixisenatide, basal insulin, type 2 diabetes, glycemic control, HbA1c, metformin, GLP-1 receptor agonists, weight change, hypoglycemia, gastrointestinal adverse effects, inadequate glycemic control
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Insulin Glargine, Aged, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Combinations, Drug Evaluation, Preclinical, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Peptides, Body Mass Index, Treatment Outcome, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.